UPB NASDAQ
Upstream Bio, Inc.
1W: -8.3%
1M: +0.6%
3M: -31.2%
YTD: -75.5%
1Y: -37.9%
$6.40
+0.00 (+0.00%)
Weekly Expected Move ±7.4%
$5
$6
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$348.3M
52W Range5.85-33.68
Volume420,707
Avg Volume578,891
Beta1.24
Dividend—
Analyst Ratings
Company Info
CEOE. Rand Sutherland
Employees75
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-11
Websiteupstreambio.com
890 Winter Street
Waltham, MA 02451
US
Waltham, MA 02451
US
781 208 2466
About Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Latest News
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GRAY MICHAEL | S-Sale | 853 | $6.10 | 2026-06-16 |
| Sutherland Everett R | S-Sale | 2,095 | $6.10 | 2026-06-16 |
| Houghton Adam | S-Sale | 700 | $6.10 | 2026-06-16 |
| Deykin Aaron | S-Sale | 895 | $6.10 | 2026-06-16 |
| Ambrose Allison | S-Sale | 477 | $6.10 | 2026-06-16 |